Diagnostic accuracy of non-contrast abdominopelvic computed tomography scans in follow-up of breast cancer patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nam, Sang Yu | - |
dc.contributor.author | Ahn, Su Joa | - |
dc.contributor.author | Jang, Young Rock | - |
dc.contributor.author | Chun, Yong Soon | - |
dc.contributor.author | Park, Heung Kyu | - |
dc.contributor.author | Choi, Seung Joon | - |
dc.contributor.author | Choi, Hye Young | - |
dc.contributor.author | Kim, Jeong Ho | - |
dc.date.available | 2021-03-08T00:40:40Z | - |
dc.date.created | 2021-02-09 | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 0007-1285 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/80317 | - |
dc.description.abstract | OBJECTIVES: To evaluate the effectiveness of follow-up with non-enhanced CT (NECT) in patients with breast cancer. METHODS: The present retrospective study included 1396 patients with breast cancer. Group A included patients with no metastasis to evaluate the diagnostic performance of NECT in detecting newly developed metastasis. Group B included patients with known hepatic metastasis to evaluate the accuracy of NECT for the assessment of hepatic metastasis. RESULTS: Group A included 895 patients (mean age 52.8 years). Among them, 145 patients had 160 metastases. The per-patient sensitivities for diagnosing newly developed metastasis were 68.3 and 53.8% according to the two reviewers, while the per-lesion sensitivities were 89.4 and 85.0%. Sensitivities for bone metastasis were 98.9 and 95.9%, while sensitivities for hepatic metastasis were 73.7 and 68.4%. In group B, the accuracy of hepatic metastasis response evaluation according to the RECIST criteria was 70.8% for reviewer 1 and 63.8% for reviewer 2. CONCLUSIONS: NECT showed inadequate diagnostic performance in detecting newly developed metastasis and in evaluating the response of hepatic metastasis. However, NECT can be utilized as a follow-up modality in patients with decreased renal function or hypersensitivity to iodinated contrast media. ADVANCES IN KNOWLEDGE: The risk of side effects of contrast media should be considered as important when NECT can be utilized as a follow-up modality in decreased renal function patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BRITISH INST RADIOLOGY | - |
dc.relation.isPartOf | The British journal of radiology | - |
dc.title | Diagnostic accuracy of non-contrast abdominopelvic computed tomography scans in follow-up of breast cancer patients | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000611404100033 | - |
dc.identifier.doi | 10.1259/bjr.20201087 | - |
dc.identifier.bibliographicCitation | The British journal of radiology, v.94, no.1118 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85100280348 | - |
dc.citation.title | The British journal of radiology | - |
dc.citation.volume | 94 | - |
dc.citation.number | 1118 | - |
dc.contributor.affiliatedAuthor | Nam, Sang Yu | - |
dc.contributor.affiliatedAuthor | Ahn, Su Joa | - |
dc.contributor.affiliatedAuthor | Jang, Young Rock | - |
dc.contributor.affiliatedAuthor | Chun, Yong Soon | - |
dc.contributor.affiliatedAuthor | Park, Heung Kyu | - |
dc.contributor.affiliatedAuthor | Choi, Seung Joon | - |
dc.contributor.affiliatedAuthor | Choi, Hye Young | - |
dc.contributor.affiliatedAuthor | Kim, Jeong Ho | - |
dc.type.docType | Article | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.